Cargando…
The power of telemedicine to improve CAR-T cell therapy programs: lessons learned from COVID-19 pandemic
PURPOSE: CAR-T programs will burden increasingly on healthcare systems, since the implementation of these therapies involves: multidisciplinary team collaboration, post-infusion hospitalization with risk of life-threatening toxicities, frequent in hospital visits and prolonged follow-up which heavil...
Autores principales: | Canale, Filippo A., Martino, Massimo, Porto, Gaetana, Verduci, Chiara, Console, Giuseppe, Irrera, Giuseppe, Loteta, Barbara, Naso, Virginia, Pugliese, Marta, Moscato, Tiziana, Ferreri, Anna, Nappi, Davide, Nicolini, Fabio, Mazza, Massimiliano, Martinelli, Giovanni, Cerchione, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209549/ https://www.ncbi.nlm.nih.gov/pubmed/37227523 http://dx.doi.org/10.1007/s00520-023-07811-6 |
Ejemplares similares
-
Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation
por: Martino, Massimo, et al.
Publicado: (2023) -
Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation
por: Martino, Massimo, et al.
Publicado: (2023) -
CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma
por: Martino, Massimo, et al.
Publicado: (2021) -
Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience
por: Loteta, Barbara, et al.
Publicado: (2021) -
Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon
por: Martino, Massimo, et al.
Publicado: (2022)